Patents Examined by Shawquia Young
  • Patent number: 9598356
    Abstract: Cyhalofop is prepared by coupling 2-(4-hydroxyphenoxy)propionic acid and 3,4-difluorobenzonitrile with base in a polar aprotic solvent in the presence of a phase-transfer catalyst.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: March 21, 2017
    Assignee: Dow AgroSciences LLC
    Inventors: Ronald B. Leng, Eric W. Otterbacher, Herbert N. Praay
  • Patent number: 8921405
    Abstract: The present invention relates to compounds of general formula I in which A, L, M, Q2, Q3, Q4, R1, R5, Ra, Rb, Rc, W, X, Y, Z1, Z2, Z3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: December 30, 2014
    Assignee: Orexo AB
    Inventors: Roland Pfau, Kirsten Arndt, Henri Doods, Klaus Klinder, Raimund Kuelzer, Dimitrijs Lubriks, Juergen Mack, Benjamin Pelcman, Henning Priepke, Robert Roenn, Dirk Stenkamp, Edgars Suna
  • Patent number: 8912344
    Abstract: A photoelectric conversion device capable of improving conversion efficiency is provided. The photoelectric conversion device includes a work electrode, a counter electrode, and an electrolyte-containing layer. In the work electrode, a metal oxide semiconductor layer supporting a dye is provided. The dye contains a cyanine compound. The cyanine compound has heterocyclic skeletons containing indolenine skeletons bonded with both ends of a methine chain, an anchor group introduced to a nitrogen atom contained in the indolenine skeletons, and a phenanthrene skeleton contained in one of the heterocyclic skeletons. In the case where light enters the dye, electron injection efficiency to the metal oxide semiconductor layer is improved.
    Type: Grant
    Filed: December 25, 2009
    Date of Patent: December 16, 2014
    Assignee: Adeka Corporation
    Inventors: Junji Tanabe, Atsushi Monden, Masahiro Shinkai, Toru Yano, Yukiko Mae, Yohei Aoyama
  • Patent number: 8912220
    Abstract: Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: December 16, 2014
    Inventors: Amy Elder, Geraldine Harriman, Silvana Leit, Jie Li, Howard Sard, Yiliang Zhang, Doug Wilson
  • Patent number: 8906952
    Abstract: The present invention relates to an indole derivative, The indole derivative according to the present invention effectively inhibits the activity of diacylglycerol acyltransferase (DGAT) which induces metabolic diseases, such as obesity, diabetes, hyperlipidemia, or fatty liver and the like in lipid metabolism, thereby effectively regulating lipid metabolism and energy metabolism, and thus can be useful in pharmaceutical compositions for preventing or treating metabolic disease.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: December 9, 2014
    Assignee: Korea Research Institute of Bioscience & Biotechnology
    Inventors: Hyun Sun Lee, Mun-Ock Kim, Yongseok Choi, Kyeong Lee, Jeong-Jun Park, Jee-Hee Seo, Hwayoung Jung, Sungchan Cho
  • Patent number: 8901318
    Abstract: Disclosed herein are processes for the preparation of a pharmaceutically active agent and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: December 2, 2014
    Assignee: H. Lundbeck A/S
    Inventors: Frans Therkelsen, Michael Harold Rock, Svend Treppendahl
  • Patent number: 8895604
    Abstract: Solid forms of (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine hydrochloride, in particular crystalline forms and/or amorphous forms thereof, pharmaceutical compositions and medicaments containing these solid forms, the use of these solid forms, and a process for obtaining such solid forms.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: November 25, 2014
    Assignee: Gruenenthal GmbH
    Inventors: Michael Gruss, Stefan Kluge, Andreas Sieber
  • Patent number: 8895596
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: November 25, 2014
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Jinlong Jiang, Andrew J. Kassick, Ahmet Kekec, Iyassu K. Sebhat
  • Patent number: 8889884
    Abstract: A phosphine derivative of DyLight dyes modified with ethylene glycol or (poly)ethylene glycol groups. In one embodiment, the compounds are useful in chemoselective ligation reactions.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: November 18, 2014
    Assignees: Pierce Biotechnology, Inc., Dyomics GmbH
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Suk J. Hong, Matthias S. Wenzel, Boguslawa Dworecki, Frank G. Lehmann
  • Patent number: 8882990
    Abstract: Embodiments of methods for making renewable diesel by deoxygenating (decarboxylating/decarbonylating/dehydrating) fatty acids to produce hydrocarbons are disclosed. Fatty acids are exposed to a catalyst selected from a) Pt and MO3 on ZrO2 (M is W, Mo, or a combination thereof), or b) Pt/Ge or Pt/Sn on carbon, and the catalyst decarboxylates at least 10% of the fatty acids. In particular embodiments, the catalyst consists essentially of 0.7 wt % Pt and 12 wt % WO3, relative to a mass of catalyst, or the catalyst consists essentially of a) 5 wt % Pt and b) 0.5 wt % Ge or 0.5 wt % Sn, relative to a mass of catalyst. Deoxygenation is performed without added hydrogen and at less than 100 psi. Disclosed embodiments of the catalysts deoxygenate at least 10% of fatty acids in a fatty acid feed, and remain capable of deoxygenating fatty acids for at least 200 minutes to more than 350 hours.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: November 11, 2014
    Assignee: Battelle Memorial Institute
    Inventors: Richard T. Hallen, Karl O. Albrecht, Heather M. Brown, James F. White
  • Patent number: 8877946
    Abstract: Compounds of general formula I: wherein R1a, R1b, R2, R3a, R3b and X are as defined herein are tyrosine kinase inhibitors and are useful for the treatment of various diseases and conditions, for example cancer.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: November 4, 2014
    Assignee: National University of Singapore
    Inventors: Mei Lin Go, Han Kiat Ho, Xiao Chen
  • Patent number: 8871784
    Abstract: Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from their activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: October 28, 2014
    Assignee: Dompe'S.p.A.
    Inventors: Alessio Moriconi, Marcello Allegretti, Maria Candida Cesta, Riccardo Bertini, Cinzia Bizzarri, Francesco Colotta
  • Patent number: 8865751
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and the compositions in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compounds of the inventions.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: October 21, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Juan-Miguel Jimenez, Ronald Knegtel, Daniel Robinson, Philip Collier
  • Patent number: 8853420
    Abstract: The present invention encompasses compounds of general formula (1), wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: October 7, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Treu, Thomas Karner, Ulrich Reiser
  • Patent number: 8846731
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogs, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: September 30, 2014
    Assignee: FerroKin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Patent number: 8846748
    Abstract: Indolyl or indolinyl compounds of formula (I): wherein bond, n, R1, R2, R3, R4, R5, and R6, are defined herein. Also disclosed is a method for treating cancer with these compounds.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: September 30, 2014
    Assignees: Taipei Medical University, Ohio State University, National Taiwan University
    Inventors: Ching-Shih Chen, Jing-Ping Liou, Hsing-Jin Liu, Kuo-Sheng Hung, Pei-Wen Shan, Wen-Ta Chiu, Che-Ming Teng
  • Patent number: 8846753
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: September 30, 2014
    Assignee: Vertex Pharamaceuticals Incorporated
    Inventors: Sara S Hadida Ruah, Mark T. Miller, Brian Bear, Jason McCartney, Peter D. J. Grootenhuis
  • Patent number: 8841464
    Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: September 23, 2014
    Assignee: Wayne State University
    Inventor: Aloke K. Dutta
  • Patent number: 8841475
    Abstract: The invention relates to a method for producing phosphoric acid triesters of formula (I). According to said method, phosphoric acid or a phosphoric acid derivative selected from orthophosphoric acid, tetraphosphoric decaoxide and polyphosphoric acid is reacted with alkoxylated alcohols of formulae (II) R1—(OA1)x—OH, (III) R2—(OA2)y—OH, and (IV) R3—(OA3)z—OH, in the molar ratio phosphoric acid or phosphoric acid derivative to alkoxylated alcohol of 1:2.5 to 1:3.3, at between 200 and 240° C.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 23, 2014
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Peter Klug, Franz-Xaver Scherl, Waltraud Simsch, Adelgunde Oberhauser
  • Patent number: 8835465
    Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: September 16, 2014
    Assignee: AstraZeneca AB
    Inventors: Audrey Molina, Michelle Lamb, Paul Lyne, Peter Mohr, Bin Wang, Tao Wang, Dingwei Yu